Portfolio 15
| Date | Name | Website | Total Raised | Location |
| - | Zafrens | zafrens.com | $29M | United Sta... |
| - | Cerapedics... | cerapedics.com | $89M | United Sta... |
| - | Venova Med... | venovamedical.com | - | - |
| - | Merck | merck.com | - | United Sta... |
| - | Biospectal... | biospectal.com | $8.4M | Switzerlan... |
| - | RIVANNA | rivannamedical.com | $31.35M | United Sta... |
| - | Eyenuk, In... | eyenuk.com | $32.2M | United Sta... |
| - | Illumicell | illumicell.ai | - | Canada, On... |
| - | Corflow | corflow.com | $48.58M | Switzerlan... |
| - | Aria CV, I... | ariacv.com | $31M | United Sta... |
Show more
Mentions in press and media 3
| Date | Title | Description |
| 12.09.2024 | CorFlow Therapeutics Secures €44 Million to Revolutionize Heart Attack Treatment | CorFlow Therapeutics is on a mission. The Swiss company has just raised €44 million in a Series B funding round, co-led by Broadview Ventures and Panakes Partners. This influx of capital is not just a financial boost; it’s a lifeline for pa... |
| 12.09.2024 | CorFlow Therapeutics raises €44 million in Series B round | Co-led by Broadview Ventures and Panakes Partners, CoFlow’s series B round received strong continued support from 415 Capital, its initial VC investor and largest shareholder. Merieux Equity Partners, Laerdal Million Lives Fund, Wellington... |
| 12.09.2024 | CorFlow Therapeutics: €44 Million (Series B) Raised For Advancing Drug Delivery Platform Related To Microvascular Obstruction In Heart Attack Patients | CorFlow Therapeutics AG announced that it has raised €44 million in Series B funding, co-led by Broadview Ventures and Panakes Partners with strong continued support from 415 Capital (CorFlow’s initial VC investor and largest shareholder). ... |